Alfacell Provides Update On The ONCONASE Phase IIIb Registration Trial (Medical News Today)
AlfacellCorporation (Nasdaq: ACEL) today provided an update on the status of theongoing confirmatory Phase IIIb registration trial evaluating ONCONASE(R)(ranpirnase), the Company's lead investigational drug candidate, as atreatment for unresectable malignant mesothelioma (UMM): Rollin [click link for full article]

Global Generics Guide: Part 2 - Benchmarking country markets and strategic issues (Pharmaceutical Business Review)
Introduction The generics market is undergoing significant change, with intense merger and acquisition activity, a raft of upcoming patent expiries and new legislation being enacted to promote generic prescription in the major markets.

FDA Avastin Approval Was Expected - Kepler (New Ratings)
0814 GMT [Dow Jones] FDA approval for Avastin from Roche (RHHBY) and Genentech (DNA) is in line with expectations, says Kepler Equities. "We expect that off-label use for the new indication is already high.